B cells and the therapeutic index of checkpoint blockade.

Preemptive rituximab-mediated B cell depletion in advanced melanoma patients receiving combined CTLA-4/PD-1 blockade is linked to fewer severe toxicities despite trial discontinuation.

• Why it matters: Combined checkpoint blockade can effectively treat melanoma but often triggers immune-related adverse events that are hard to manage and can force treatment disruption or stopping.
• What they did: Dhodapkar and colleagues analyzed data from a small randomized clinical trial in advanced melanoma testing rituximab-mediated B cell depletion during CTLA-4/PD-1 blockade, which was stopped early due to rituximab hypersensitivity.
• The result: B cell depletion was associated with reduced severe toxicities without evident loss of antitumor activity, informing questions about checkpoint-induced autoimmunity and immune reset.

AI summary of the abstract · may contain errors · not medical advice · read the paper.